121 related articles for article (PubMed ID: 12376150)
1. SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study.
Bass CE; Griffin G; Grier M; Mahadevan A; Razdan RK; Martin BR
Pharmacol Biochem Behav; 2002 Dec; 74(1):31-40. PubMed ID: 12376150
[TBL] [Abstract][Full Text] [Related]
2. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
3. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
4. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues.
Stamer WD; Golightly SF; Hosohata Y; Ryan EP; Porter AC; Varga E; Noecker RJ; Felder CC; Yamamura HI
Eur J Pharmacol; 2001 Nov; 431(3):277-86. PubMed ID: 11730719
[TBL] [Abstract][Full Text] [Related]
6. SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine.
Masserano JM; Karoum F; Wyatt RJ
Behav Pharmacol; 1999 Jul; 10(4):429-32. PubMed ID: 10780811
[TBL] [Abstract][Full Text] [Related]
7. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.
Bouaboula M; Perrachon S; Milligan L; Canat X; Rinaldi-Carmona M; Portier M; Barth F; Calandra B; Pecceu F; Lupker J; Maffrand JP; Le Fur G; Casellas P
J Biol Chem; 1997 Aug; 272(35):22330-9. PubMed ID: 9268384
[TBL] [Abstract][Full Text] [Related]
8. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
Pan X; Ikeda SR; Lewis DL
Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635
[TBL] [Abstract][Full Text] [Related]
9. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
Adams IB; Compton DR; Martin BR
J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
[TBL] [Abstract][Full Text] [Related]
10. Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamine-induced hyperactivity.
Miller DK; Rodvelt KR; Constales C; Putnam WC
Life Sci; 2007 Jun; 81(1):63-71. PubMed ID: 17532007
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
Lay L; Angus JA; Wright CE
Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
[TBL] [Abstract][Full Text] [Related]
12. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
Darmani NA
Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
[TBL] [Abstract][Full Text] [Related]
13. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
Lichtman AH; Fisher J; Martin BR
Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
[TBL] [Abstract][Full Text] [Related]
14. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat.
Martin RS; Secchi RL; Sung E; Lemaire M; Bonhaus DW; Hedley LR; Lowe DA
Psychopharmacology (Berl); 2003 Jan; 165(2):128-35. PubMed ID: 12404071
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
[TBL] [Abstract][Full Text] [Related]
16. WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release.
Rodvelt KR; Bumgarner DM; Putnam WC; Miller DK
Life Sci; 2007 Jan; 80(4):337-44. PubMed ID: 17067637
[TBL] [Abstract][Full Text] [Related]
17. Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice.
Darmani NA; Pandya DK
J Neural Transm (Vienna); 2000; 107(8-9):931-45. PubMed ID: 11041273
[TBL] [Abstract][Full Text] [Related]
18. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.
Navarro M; Hernández E; Muñoz RM; del Arco I; Villanúa MA; Carrera MR; Rodríguez de Fonseca F
Neuroreport; 1997 Jan; 8(2):491-6. PubMed ID: 9080435
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats.
Fattore L; Spano S; Cossu G; Deiana S; Fadda P; Fratta W
Neuropharmacology; 2005 Jun; 48(8):1097-104. PubMed ID: 15910886
[TBL] [Abstract][Full Text] [Related]
20. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats.
Costa B; Vailati S; Colleoni M
Behav Pharmacol; 1999 May; 10(3):327-31. PubMed ID: 10780247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
